These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

535 related items for PubMed ID: 26093811

  • 1. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
    Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damião R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ.
    Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
    [Abstract] [Full Text] [Related]

  • 2. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.
    Body JJ, von Moos R, Niepel D, Tombal B.
    BMC Urol; 2018 Sep 20; 18(1):81. PubMed ID: 30236112
    [Abstract] [Full Text] [Related]

  • 3. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
    Huynh AL, Baker ST, Stewardson AJ, Johnson DF.
    Pharmacoepidemiol Drug Saf; 2016 Nov 20; 25(11):1274-1278. PubMed ID: 27255807
    [Abstract] [Full Text] [Related]

  • 4. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
    Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.
    Eur J Cancer; 2012 Nov 20; 48(16):3082-92. PubMed ID: 22975218
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Denosumab and bone metastases. No better than a bisphosphonate.
    Prescrire Int; 2012 Sep 20; 21(130):204-6. PubMed ID: 23016249
    [Abstract] [Full Text] [Related]

  • 7. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
    Kinoshita Y, Arai M, Ito N, Takashi Y, Makita N, Nangaku M, Shinoda Y, Fukumoto S.
    Endocr J; 2016 May 31; 63(5):479-84. PubMed ID: 26860123
    [Abstract] [Full Text] [Related]

  • 8. Hypocalcaemia following denosumab in prostate cancer: A clinical review.
    Lau LH, Cliff ERS, Wong V, Wong H, Torkamani N, Eer A, Weickhardt A, Grossmann M.
    Clin Endocrinol (Oxf); 2020 Jun 31; 92(6):495-502. PubMed ID: 32017154
    [Abstract] [Full Text] [Related]

  • 9. Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia.
    Imatoh T, Sai K, Takeyama M, Hori K, Karayama M, Furuhashi K, Segawa K, Kimura M, Kawakami J, Saito Y.
    J Clin Pharm Ther; 2019 Feb 31; 44(1):62-68. PubMed ID: 30144112
    [Abstract] [Full Text] [Related]

  • 10. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
    Nasser SM, Sahal A, Hamad A, Elazzazy S.
    J Oncol Pharm Pract; 2019 Dec 31; 25(8):1846-1852. PubMed ID: 31694497
    [Abstract] [Full Text] [Related]

  • 11. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C.
    Lancet; 2011 Mar 05; 377(9768):813-22. PubMed ID: 21353695
    [Abstract] [Full Text] [Related]

  • 12. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
    Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD.
    Eur Urol; 2014 Feb 05; 65(2):278-86. PubMed ID: 23706567
    [Abstract] [Full Text] [Related]

  • 13. Use and safety of denosumab in cancer patients.
    Manzaneque A, Chaguaceda C, Mensa M, Bastida C, Creus-Baró N.
    Int J Clin Pharm; 2017 Jun 05; 39(3):522-526. PubMed ID: 28382583
    [Abstract] [Full Text] [Related]

  • 14. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
    Laskowski LK, Goldfarb DS, Howland MA, Kavcsak K, Lugassy DM, Smith SW.
    J Med Toxicol; 2016 Sep 05; 12(3):305-8. PubMed ID: 26987988
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.
    Lipton A, Smith MR, Fizazi K, Stopeck AT, Henry D, Brown JE, Shore ND, Saad F, Spencer A, Zhu L, Warner DJ.
    Clin Cancer Res; 2016 Dec 01; 22(23):5713-5721. PubMed ID: 27140926
    [Abstract] [Full Text] [Related]

  • 17. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, Legieć W, Krejčí M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD.
    Lancet Oncol; 2018 Mar 01; 19(3):370-381. PubMed ID: 29429912
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.
    J Clin Oncol; 2011 Mar 20; 29(9):1125-32. PubMed ID: 21343556
    [Abstract] [Full Text] [Related]

  • 19. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
    Saito Y, Takekuma Y, Komatsu Y, Sugawara M.
    Biol Pharm Bull; 2021 Mar 20; 44(12):1819-1823. PubMed ID: 34853264
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.